ClinicalTrials.gg
CompletedNCT02074579Updated May 2, 2017

A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

A Phase 2 interventional study of TU-100 and Placebo in Irritable Bowel Syndrome in Females, sponsored by Tsumura USA. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Tsumura USA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 344 studies in Irritable Bowel Syndrome with a site in United States — 45 open to participants now, 49 under way, 3 of them phase 3. Irritable Bowel Syndrome · United States.

Enrollment
105th of 287
101 · median 61
Started
2014
with 20 others
Phase 2
80 of 344
8 open now
Registered
140th of 344
by date

Among the 344 studies in Irritable Bowel Syndrome with a site in United States, this one is the 105th largest by enrollment of the 287 interventional ones that give a count, is one of 21 that started in 2014, is one of 80 in phase 2, and was the 140th registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

45 of the 344 studies in Irritable Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Irritable Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to assess the effect of orally administered TU-100 (5 g three times daily [TID]) as compared to placebo on abdominal bloating rating in female IBS patients.

03

Conditions studied

  • Irritable Bowel Syndrome in Females

Keywords

  • Irritable Bowel Syndrome
  • Rome III criteria
  • abdominal bloating
  • natural
  • herbal
  • Kampo
  • Adult ages 18 to 65
  • Female subjects
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet Rome III criteria for IBS (any subtype)
  • Female aged 18 to 65 years, inclusive
  • If of , prepared to use suitable forms of throughout the study and for 30 days after the last dose i.e., hormonal contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing, Essure), condoms used with a spermicide, an intrauterine device, or abstinence. Females are not considered to be of childbearing potential if they are naturally (no menses for at least 1 year and, if \< 55 years of age, have a documented follicle-stimulating hormone [FSH] level of ≥ 35 mIU/mL) or have documentation of surgical sterility
  • Have a between 18 and 30 kg/m2, inclusive
  • Have a negative pregnancy urine screening at Visit 1, if of childbearing potential
  • Able to provide written consent
  • Able to take oral administration of the testing medications
  • Have a self-reported average abdominal bloating rating (>3 daily ratings over the preceding 7 days) equal or greater than 4 on a numerical scale of 0 to 20.

Exclusion criteria

Exclusion Criteria:

  • Have a structural or metabolic disease or condition that affects the GI system, excluding asymptomatic gallstones or uncomplicated gastroesophageal reflux disease, or any medical condition that may be a cause of constipation or diarrhea (e.g., hypothyroid status, poorly controlled diabetes, diabetic neuropathy or autonomic neuropathy)
  • Be taking any medication that, in the opinion of the Principle Investigator (PI), has potential to alter GI transit. A full list of prohibited medications is provided in the protocol. Have history or presence of any chronic lung disease
  • Have presence of hepatic dysfunction, jaundice, or abnormal serum (ALT) or aspartate aminotransferase (AST) values exceeding 2.5 x
  • Currently pregnant or lactating
  • Have a positive urine drug test at screening (subjects who initially test positive will be allowed one retest)
  • Be a known substance abuser or be considered to be an alcoholic not in remission
  • Have participated in another clinical study in the past 30 days
  • Use of supplemental ginger, ginseng, or Zanthoxylum fruit for 2 weeks prior to randomization and throughout the course of the study.
  • Have a history of allergic reaction to ginseng, ginger or Zanthoxylum fruit
  • Be clinically lactose-intolerant
  • Have any other condition that, in the opinion of the PI, causes the subject to be unsuitable to participate
  • Have taken antibiotics in the last 3 months
  • Have had gastroenteritis ("stomach flu") in the last 3 months
  • Have taken probiotics in the last 3 months (over-the-counter [OTC] products or supplements only; food products such as yogurts are permitted).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    TU-100

    15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)

    Drug: TU-100

  • Placebo comparator
    Matching placebo

    Matching placebo given 5g three times daily orally for 4 consecutive weeks

    Drug: Placebo

Interventions

  • DrugTU-100

    15g daily, orally as 5g three times daily for 4 consecutive weeks

    Also known as: Daikenchuto

  • DrugPlacebo

    Matching placebo given 5g three times daily orally for 4 consecutive weeks

06

What researchers measure

Primary outcomes

  1. Abdominal bloating rating

    Change in abdominal bloating rating, through comparison of the change in average ratings from the 7 days prior to baseline (Visit 2) to the last 7 days of the 4 week treatment period (Visit 4), between TU-100 15 g and placebo.

    Time frame: 4 weeks

Secondary outcomes

  1. AUC for abdominal bloating ratings using lactulose challenge

    Change in area under the curve (AUC) for abdominal bloating ratings obtained during the lactulose challenge at Visit 2 (baseline) and at Visit 4 (4 weeks). The data are collected at -0.5, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 hours after taking test meal (lactulose).

    Time frame: Baseline and 4 weeks

  2. Abdominal bloating ratings

    Change in the average of abdominal bloating ratings from the 7 days prior to baseline to the 7 days prior to Visit 3 (2 weeks) and to Visit 5 (8 weeks)

    Time frame: 4 weeks

  3. Overall IBS Severity

    Change in Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) total score from baseline to Visits 3, 4, and 5

    Time frame: 4 weeks

  4. GI symptom ratings

    Change in the average of GI symptom ratings from the 7 days prior to baseline to the 7 days prior to Visit 3 and to Visit 5

    Time frame: 4 week

  5. Quality of Life effect

    Change in IBS-QOL score from baseline to Visits 3, 4, and 5

    Time frame: 4 weeks

  6. Mood symptom ratings

    Change in the average of mood symptom ratings from the 7 days prior to baseline to the 7 days prior to Visit 3 and to Visit 5

    Time frame: 4 weeks

Other outcomes

  1. Physical Examination

    Physical examination at Visits 1, 2 and 4

    Time frame: 4 weeks

  2. Vital Signs

    2. Vital signs (pulse, blood pressure, temperature, and respiration rate) at Visits 1, 2 and 4

    Time frame: 4 weeks

  3. Adverse Events and Concomitant Medications

    Interview for adverse events (AEs) and concomitant medications at Visits 3, 4 and 5

    Time frame: 8 weeks

  4. Laboratory safety tests

    Laboratory safety tests including hematology, chemistry, and urinalysis at Visits 1, 2 and 4. Pregnancy test for subjects of childbearing potential at Visits 1, 2, 3, 4 and 5.

    Time frame: 8 weeks

07

Study locations

1 site
  • Oppenheimer Family Center for Neurobiology of Stress Division of Digestive Diseases David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2014
First posted
Feb 28, 2014
Start
Jul 2014
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results delay requested
Apr 28, 2017
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02074579
Lead sponsor
Tsumura USA
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
Feb 28, 2014
Start date
Jul 2014
Primary completion
Apr 2016
Completion
Apr 2016
Last update
May 2, 2017

Study contacts

Kirsten Tillisch, MD
principal investigator · Oppenheimer Family Center of Neurobiology of Stress, UCLA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tu-100

Start the discussion